- Joined
- Mar 28, 2026
- Messages
- 4,927
- Solutions
- 12
- Reputation
- 10,445
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
BONE MORPHOGENETIC PROTEINS AND HEIGHT
BMP signaling | growth plate biology | chondrogenesis | what the science says
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
all citations are real peer-reviewed papers.
this is what the literature actually shows, presented directly.
[1] Nilsson O et al. (2007) Endocrinology. BMP-2 regulation of growth plate chondrogenesis and longitudinal bone growth
[2] Yoon BS, Lyons KM. (2004) J Cell Biochem. Multiple functions of BMPs in chondrogenesis
[3] Pogue R, Lyons K. (2006) Curr Top Dev Biol. BMP signaling in the cartilage growth plate
[4] Robert C et al. (2023) JBC. BMP-2 and Noggin interaction: molecular details of chondrogenesis inhibition
[5] Nilsson O et al. (2007) PLOS ONE. Spatial regulation of BMPs across growth plate zones
[6] Clinical and Experimental Pediatrics (2023). Growth plate closure and therapeutic interventions. PMC11551597
[7] Choi S et al. (2019) Mol Brain. Indirubin-3-oxime stimulates chondrocyte maturation via Wnt/BMP
[8] Yazaki Y et al. (1998) Spine. BMP-2/4 and OP-1 expression in rat epiphyseal growth plate
[9] Suttapreyasri S, Leepong N. (2013) J Craniofac Surg. BMP-2/7 and growth plate chondrocytes
[10] Kawai M et al. (2006) BMC MSK. BMP-2 and BMP-7 simultaneous gene transfer induces rapid bone formation
[11] Garrison KR et al. (2010) Health Technol Assess. rhBMP-2 review: evidence and complications
[12] Nature npj (2023). BMP2-hydrogel local therapy: growth plate fusion risk noted
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
CONTENTS
01 what BMPs are and how many exist
02 the growth plate how height actually happens
03 which BMPs are expressed in the growth plate and where
04 BMP-2 the primary chondrogenic driver mechanism in full
05 BMP-4 BMP-7 and the heterodimer effect
06 BMP antagonists Noggin Gremlin sclerostin why the brake exists
07 the Smad and non-Smad signaling cascades
08 the paradox too much BMP accelerates plate closure
09 growth plate closure why it happens and what drives it
10 therapeutic interventions that actually delay closure and increase height
11 what exogenous BMP could theoretically do and what the evidence shows
12 the honest translation open plates vs closed plates
13 verdict
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
01 WHAT BMPs ARE AND HOW MANY EXIST
Bone Morphogenetic Proteins (BMPs) are secreted signalling proteins
belonging to the TGF-beta superfamily. Despite their name, not all BMPs
promote bone formation. They are involved in embryonic patterning, organ
development, neural differentiation, and skeletal biology across species.
20 distinct BMPs have been identified in humans.
They signal through type I and type II serine-threonine kinase receptors.
Their activity is modulated by extracellular antagonists and co-receptors.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
THE BMP FAMILY RELEVANT TO HEIGHT
BMP-2
Most studied. Expressed throughout growth plate proliferative and hypertrophic zones. Primary driver of chondrocyte proliferation and hypertrophy. Confirmed to accelerate longitudinal bone growth concentration-dependently (Nilsson et al. 2007). The central figure of this thread.
BMP-4
Structural homolog of BMP-2. Co-expressed with BMP-2 in growth plate chondrocytes (Yazaki et al. 1998: marked expression in proliferating and maturing chondrocytes at 12 weeks in rat tibia). Forms heterodimers with BMP-7. Synergises with BMP-2 in osteochondral induction.
BMP-7 (OP-1)
Osteogenic Protein-1. Expressed in proliferating and maturing chondrocytes alongside BMP-2/4 (Yazaki 1998). Forms highly active heterodimers with BMP-2 and BMP-4. Kawai et al. 2006: simultaneous BMP-2 and BMP-7 gene transfer produced dramatically higher ALP activity and faster bone formation than either alone.
BMP-6
Expressed in hypertrophic chondrocytes of the growth plate. Role in regulating hypertrophic differentiation and eventual plate calcification. Less studied than BMP-2/4/7 in the height context.
GDF-5 (BMP-14)
Growth and Differentiation Factor 5. Expressed in joint interzone regions and growth plate. Loss-of-function mutations in humans cause brachydactyly type C (short fingers) and Grebe syndrome. Promotes chondrocyte differentiation. Dose-sensitive.
BMP-3
Paradoxical: BMP-3 is an INHIBITOR of bone formation and chondrogenesis. Acts as a negative regulator by competing at receptors. Elevated BMP-3 activity suppresses longitudinal growth. Not a therapeutic target for height increase.
BMP-9 (GDF-2)
Highly osteoinductive in vitro. Does not appear to play a primary role in growth plate chondrogenesis specifically. More relevant to osteoblast differentiation than chondrocyte function.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
02 THE GROWTH PLATE HOW HEIGHT ACTUALLY HAPPENS
Height is determined by longitudinal bone growth.
Longitudinal bone growth occurs at the epiphyseal growth plate.
The growth plate sits between the epiphysis and metaphysis of long bones.
When it closes, height stops. This is the fundamental constraint.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
THE THREE ZONES OF THE GROWTH PLATE
RESTING ZONE (reserve zone)
Small, sparsely distributed chondrocytes. Act as progenitor cells.
Slow replication rate. Supply progenitors to the proliferative zone.
BMP signalling maintains these cells in a quiescent state.
When progenitor cells here are depleted, growth plate senescence begins.
PROLIFERATIVE ZONE (columnar zone)
Flat chondrocytes arranged in columns along the long axis of the bone.
Replicate rapidly. This is where most of the actual height is generated.
BMP-2 is the primary driver of chondrocyte proliferation in this zone.
More cell divisions = more cells added to the column = more bone length.
HYPERTROPHIC ZONE
Chondrocytes undergo dramatic enlargement (hypertrophy).
Hypertrophic chondrocytes can increase their volume by 5-10x.
This enlargement directly contributes to longitudinal bone length.
Hypertrophic zone provides approximately 60% of total longitudinal growth.
BMP-2 stimulates hypertrophic differentiation in this zone.
Calcification occurs here. Vascular invasion. Bone replaces cartilage.
THE GROWTH PROCESS IN SEQUENCE
01 progenitors from resting zone enter proliferative zone
02 BMP-2 drives rapid chondrocyte division in columnar arrangement
03 daughter cells exit proliferative zone and hypertrophy
04 hypertrophic cells secrete collagen X and mineralisation signals
05 osteoblasts and blood vessels invade and replace hypertrophic cartilage with bone
06 new bone is added to the metaphysis. the bone is longer.
07 repeat continuously until plate senescence
Clinical and Experimental Pediatrics 2023 (PMC11551597):
the proliferative and hypertrophic zone activity, and the size of hypertrophic
chondrocytes, are the primary determinants of the rate of longitudinal growth.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
03 WHICH BMPs ARE EXPRESSED IN THE GROWTH PLATE AND WHERE
Yazaki et al. 1998 (Spine): immunohistochemical mapping of BMP-2/4,
OP-1 (BMP-7), and BMP receptors (BMPR-IA, BMPR-IB, BMPR-II) in rat
tibial growth plates at 12 and 24 weeks.
AT 12 WEEKS (actively growing plate):
BMP-2/4 and BMP-7: marked expression in proliferating and maturing chondrocytes
BMPR-IA, IB and II: clearly co-expressed in proliferating and maturing chondrocytes
BMPR expression decreased in hypertrophic chondrocytes
AT 24 WEEKS (plate beginning to senesce):
BMP-2/4 and BMP-7 expression decreased significantly
BMPR receptors still well-expressed in remaining proliferating chondrocytes
Temporal reduction of BMP ligand expression correlates with plate senescence.
Nilsson et al. (PLOS ONE 2017): BMP gradient analysis across growth plate zones.
BMP-related gene expression forms gradients from resting to hypertrophic zone.
Active BMP signalling confirmed in proliferative zone.
Smad7 (inhibitory Smad) quenches BMP signalling in the hypertrophic zone,
creating a natural dampening mechanism at the terminal differentiation stage.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
04 BMP-2 THE PRIMARY CHONDROGENIC DRIVER
Nilsson et al. 2007 (Endocrinology): the foundational growth plate BMP-2 study.
Fetal rat metatarsal bones cultured for 3 days with recombinant human BMP-2.
WHAT BMP-2 DID IN THIS EXPERIMENT
concentration-dependent acceleration of metatarsal longitudinal growth
stimulated chondrocyte proliferation in the epiphyseal zone (3H-thymidine assay)
increased chondrocyte hypertrophy (quantitative histology + enzyme histochemistry)
at highest dose: stimulated proteoglycan synthesis (glycosaminoglycan production)
THE NOGGIN CONFIRMATION THE MOST IMPORTANT FINDING
Noggin is an extracellular BMP antagonist. It binds BMP-2 and blocks its
receptor interaction. Adding Noggin reverses BMP-2's effects.
Key finding: when Noggin was added WITHOUT any exogenous BMP-2:
longitudinal bone growth decreased
chondrocyte proliferation decreased
chondrocyte hypertrophy decreased
This proves endogenous BMP-2 is actively driving growth in normal bone.
Block it: growth slows. Supplement it: growth accelerates.
BMP-2 is not a permissive signal. It is an active driver.
BMP-2 MOLECULAR MECHANISM AT THE GROWTH PLATE
BMP-2 binds BMPR-IA (ALK3) and BMPR-IB (ALK6) with BMPR-II as co-receptor.
Receptor complex phosphorylates R-Smads (Smad1, Smad5, Smad8).
R-Smad/Smad4 complex enters nucleus.
Activates Sox9 (master chondrocyte transcription factor).
Sox9 drives collagen II and aggrecan expression.
Drives Runx2 for hypertrophic differentiation.
Drives cell cycle progression via cyclin D1.
Net: more chondrocytes, bigger chondrocytes, more matrix. Longer bone.
NF-kB specifically activates BMP-2 gene expression in growth plate
chondrocytes both in vivo and in vitro (ScienceDirect, confirmed in vivo).
Inflammatory and mechanical signals feed back into BMP-2 transcription.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
05 BMP-4 BMP-7 AND THE HETERODIMER EFFECT
THE HETERODIMER DISCOVERY
BMPs naturally form both homodimers (BMP-2:BMP-2) and heterodimers
(BMP-2:BMP-7, BMP-4:BMP-7).
Heterodimers are significantly more potent than either homodimer alone.
Kawai et al. 2006 (BMC MSK): simultaneous gene transfer of BMP-2 and BMP-7
into rat calf muscles produced:
dramatically higher ALP activity vs either gene alone
better-defined bone opacities on soft X-ray at 10 days
advanced ossification on histological examination
BMP-4 mRNA also induced in response to the double transfer
The BMP-2 + BMP-7 combination does not simply add their effects.
It multiplies them. The heterodimer is a distinct, more potent ligand.
BMP-4 AT THE GROWTH PLATE
Co-expressed with BMP-2 in proliferating and maturing chondrocytes.
Shares BMPR-IA/BMPR-IB receptor preference with BMP-2.
Loss of Noggin (which blocks BMP-2/4/7) in mice: overgrowth of skeletal elements.
Misexpression of Noggin in chick limbs: reduction of skeletal elements.
Direct confirmation that BMP-4 activity is required for normal skeletal growth.
BMP-7 (OP-1) AT THE GROWTH PLATE
Yazaki 1998: OP-1 expressed markedly in proliferating and maturing chondrocytes
alongside BMP-2/4. The spatial co-expression pattern suggests cooperative action.
BMP-7 predominantly forms heterodimers with BMP-2 or BMP-4 in vivo.
Frontiers 2023: BMP-2 and BMP-7 synergise in osteochondrogenesis ex vivo.
Their combination stimulates both chondrogenic and osteogenic differentiation.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
06 BMP ANTAGONISTS NOGGIN GREMLIN SCLEROSTIN
BMP signalling in the growth plate is not unopposed. A system of extracellular
antagonists modulates BMP activity with spatial and temporal precision.
Understanding these antagonists is the key to understanding why the growth
plate eventually closes and what controls the rate of growth.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
NOGGIN
A cystine knot protein that binds BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, and GDF-5.
Robert et al. 2023 (JBC): crystal structure of BMP-2:Noggin complex resolved.
Noggin occupies the type I receptor binding epitope of BMP-2.
BMP-2 cannot bind BMPR-IA while Noggin is occupying the same site.
Noggin-BMP-2 Kd: approximately 0.02 nM. Extremely high affinity.
Noggin is the primary spatial regulator of BMP activity in the growth plate.
Functional consequence confirmed (Nilsson 2007):
Noggin added to cultured bone: growth slows, proliferation drops, hypertrophy drops.
Noggin removed from context: BMP-2 drives accelerated growth.
GREMLIN
DAN family antagonist. Binds BMP-2, BMP-4, BMP-7 with high affinity.
Expressed in the interdigital zone and joint-forming regions during development.
Frontiers 2023: Gremlin cannot induce fibrous differentiation on its own.
Works in concert with TGF-beta to control chondrocyte fate decisions.
SCLEROSTIN (SOST gene)
The connection to the Romosozumab thread. Sclerostin was identified as a
DAN family BMP antagonist with homology to Noggin (Winkler et al. 2003 EMBO J).
Primarily expressed by osteocytes. Inhibits BMP activity AND Wnt/LRP5-6.
Less well-characterised at the growth plate specifically than in mature bone.
Sclerosteosis patients (no sclerostin): skeletal overgrowth from childhood.
The BMP-inhibiting function of sclerostin is part of why these patients
have excess skeletal mass but also why Romosozumab's bone building works.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
07 THE SMAD AND NON-SMAD SIGNALING CASCADES
CANONICAL SMAD PATHWAY (primary growth plate mechanism)
BMP-2 binds BMPR-IA and BMPR-IB (type I) + BMPR-II (type II)
Type II receptor trans-phosphorylates type I receptor GS domain
Activated type I receptor phosphorylates R-Smads: Smad1, Smad5, Smad8
R-Smads complex with Co-Smad: Smad4
Complex translocates to nucleus
Activates BMP-responsive genes:
Sox9 master chondrocyte regulator, drives collagen II and aggrecan
Runx2 initiates hypertrophic differentiation
Id1/Id2 inhibitor of differentiation proteins, maintain progenitor state
ColII collagen type II, primary cartilage matrix protein
ColX collagen type X, marker of hypertrophic chondrocytes
VEGF drives vascular invasion of hypertrophic zone
Inhibitory Smads (Smad6, Smad7) compete with R-Smads to limit signalling.
Smad7 is specifically upregulated in the hypertrophic zone (Nilsson PLOS ONE).
This natural braking prevents excessive hypertrophic stimulation.
NON-SMAD PATHWAYS
BMP-2 also activates:
p38 MAPK stress kinase, additional chondrocyte differentiation driver
ERK1/2 proliferation and survival signalling
PI3K/Akt cell survival and growth factor signalling
TAK1 TGF-beta activated kinase 1, crosstalk with inflammatory signals
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
08 THE PARADOX TOO MUCH BMP ACCELERATES PLATE CLOSURE
This is the most important nuance in the whole thread.
More BMP is not always better for height. There is an optimal range.
WHAT HAPPENS WITH CONSTITUTIVELY ACTIVE BMP RECEPTOR
Nilsson et al. (PLOS ONE 2017): when constitutively active BMPR-IA was
expressed in cartilage, proliferative zone height was SHORTENED.
Chondrocyte proliferation was not affected.
But hypertrophic differentiation was ACCELERATED.
Interpretation: excessive BMP signalling pushes proliferative chondrocytes
into hypertrophy faster than they can be replaced by progenitors.
The proliferative zone shrinks. The plate thins. Growth rate decreases.
In extreme cases: premature growth plate closure.
Nature npj (2023): local BMP-2 hydrogel therapy in a porcine model of
Legg-Calve-Perthes disease showed increased areas of growth plate fusion.
The authors specifically warned: BMP-2 treatment may promote plate closure.
This is why the authors noted it may be most appropriate for patients
whose growth plates are not active.
THE DOSE-TIMING WINDOW
BMP-2 drives growth when it promotes PROLIFERATION faster than HYPERTROPHY.
BMP-2 closes the plate when it drives HYPERTROPHY faster than PROLIFERATION.
The balance between these two effects is dose-dependent and timing-dependent.
Nilsson 2007: lower doses stimulate growth. Higher doses may shift the balance.
There is no established therapeutic window for human height augmentation.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
09 GROWTH PLATE CLOSURE WHY IT HAPPENS
Clinical and Experimental Pediatrics 2023 (PMC11551597):
Growth plate senescence is the process that ends height.
THE SENESCENCE MECHANISM
progenitor cells in the resting zone are gradually depleted over time
proliferative chondrocyte numbers decrease
hypertrophic chondrocyte number and size decrease
the plate thins progressively
after senescence: hypertrophic chondrocytes replaced by osteocytes
extracellular matrix calcified and vascularised
growth plate fused: longitudinal bone growth complete
WHAT DRIVES CLOSURE THE PRIMARY SIGNALS
estrogen the primary closure signal. Both males and females.
testosterone is aromatised to estrogen which acts on the plate.
estrogen receptor alpha on chondrocytes accelerates hypertrophy.
this is why aromatase inhibitors delay closure and add height.
IGF-1 drives proliferative zone activity. works synergistically with BMPs.
GH stimulates local IGF-1 production in the growth plate.
thyroid hormone required for normal hypertrophic differentiation.
glucocorticoids at excess: severely impair growth (anti-proliferative).
TIMING OF CLOSURE IN HUMANS
distal radius and ulna: typically 16-18 years females / 18-20 years males
femur distal epiphysis: 17-19 years females / 18-20 years males
tibial proximal plate: 16-18 years females / 18-20 years males
vertebral growth plates: can remain partially active into early 20s
individual variation is significant. genetics are the primary determinant.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
10 THERAPEUTIC INTERVENTIONS THAT ACTUALLY DELAY CLOSURE AND INCREASE HEIGHT
These are real approved or investigational treatments with clinical evidence.
They are presented because they reveal the upstream pathway that BMPs feed into.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
GnRH ANALOGUES (leuprolide, triptorelin)
Suppress LH and FSH. Delay puberty. Delay estrogen-driven plate closure.
Used in precocious puberty to preserve height potential.
Effect: several additional centimetres of final height in clinical use.
Mechanism: reduce estrogen that drives closure. BMP signalling continues.
AROMATASE INHIBITORS (letrozole, anastrozole)
Block testosterone-to-estrogen conversion. Reduce closure signal.
Letrozole in adolescent males with growth failure: significant height gains.
Clinical and Experimental Pediatrics 2023: AI use delays growth plate closure
and increases predicted adult height. Off-label in most countries for this use.
C-TYPE NATRIURETIC PEPTIDE ANALOGUE (vosoritide)
FDA approved 2021 for children with achondroplasia (FGFR3 gain of function).
FGFR3 normally limits BMP signalling and chondrocyte proliferation.
CNP counteracts FGFR3 suppression, restoring BMP-driven growth plate activity.
In achondroplasia trials: increased annualised growth velocity significantly.
Mechanism directly involves restoring BMP-responsive growth plate activity.
FGFR3 INHIBITORS (infigratinib, palovarotene)
FGFR3 (fibroblast growth factor receptor 3) is a negative regulator of growth.
It suppresses BMP signalling and chondrocyte proliferation.
Inhibiting FGFR3 releases the brake on BMP activity at the plate.
Phase 3 trials ongoing in achondroplasia. Pre-clinical efficacy confirmed.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
11 WHAT EXOGENOUS BMP COULD THEORETICALLY DO
Taking the literature seriously: what would exogenous BMP administration
actually do if it reached the growth plate in sufficient concentration?
THE THEORETICAL POSITIVE CASE (open plates only)
Increased BMP-2 at the proliferative zone would:
accelerate chondrocyte division (confirmed, Nilsson 2007)
increase hypertrophic zone chondrocyte size (confirmed, Nilsson 2007)
upregulate Sox9 and ColII, maintaining chondrocyte phenotype
increase proteoglycan synthesis at high dose
theoretically: faster growth rate during the open plate window
THE PROBLEMS WITH EXOGENOUS BMP FOR HEIGHT
PROBLEM 1 DELIVERY TO THE GROWTH PLATE
The growth plate has a specific vascular supply. Systemic BMP administration
does not preferentially accumulate at growth plate chondrocytes.
BMP-2 half-life in vivo without carrier: approximately 7-16 minutes.
Local delivery to the growth plate is surgically invasive.
Topical or oral administration has no evidence of reaching the plate.
PROBLEM 2 THE CLOSURE PARADOX
As established in section 08: supraphysiological BMP at the plate
accelerates hypertrophic differentiation and can cause premature closure.
Nature npj 2023: local BMP-2 hydrogel increased growth plate fusion areas.
Attempting to use BMP to grow taller could close the plate faster.
PROBLEM 3 NO HUMAN TRIALS
No clinical trial has administered any BMP preparation to growing humans
for the purpose of height increase. All mechanistic data is animal or ex vivo.
The jump from rat metatarsal culture to human height augmentation
is not supported by any current clinical evidence.
PROBLEM 4 RHBMP-2 COMPLICATIONS AT SUPRAPHYSIOLOGICAL DOSES
See the rhBMP-2 thread for the full complication profile.
Ectopic bone, osteolysis, cancer signal, cardiovascular effects.
These are documented from orthopaedic surgical use, not height augmentation.
Applying that compound systemically to a growing adolescent is not studied.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
12 THE HONEST TRANSLATION OPEN PLATES VS CLOSED PLATES
IF YOUR GROWTH PLATES ARE STILL OPEN (typically under 18-20)
BMP signalling is already actively driving your height.
It is one of the primary endogenous systems doing exactly this.
The question of augmenting it exogenously runs into the delivery
problem and the paradoxical closure risk from supraphysiological dosing.
What IS evidence-based for maximising height in this window:
adequate sleep (GH pulse is largest during slow-wave sleep)
adequate nutrition: zinc, vitamin D, protein, calories
avoid glucocorticoid excess (suppresses BMP-driven chondrocyte proliferation)
avoid smoking (vasoconstrictive effects on growth plate vasculature)
treat any underlying endocrine issues (hypothyroidism impairs growth)
IF YOUR GROWTH PLATES ARE CLOSED (typically over 20-22)
No BMP intervention can reopen a fused growth plate.
Fused plates are bone. BMPs drive bone formation, not plate reopening.
The only interventions that affect height after closure:
spinal decompression / posture (millimetric, not centimetric)
limb lengthening surgery (Ilizarov / PRECICE nail: 5-8cm possible, major surgery)
No pharmacological intervention currently increases height after plate closure.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
13 VERDICT
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
WHAT THE SCIENCE DEFINITIVELY SHOWS
BMPs, primarily BMP-2, are essential endogenous drivers of longitudinal bone growth.
They are expressed in the growth plate, they drive chondrocyte proliferation,
they stimulate hypertrophy, and blocking them with Noggin slows growth.
The biology is not in dispute. BMPs are part of how you grew tall.
THE ACTUAL OPPORTUNITY IN BMP BIOLOGY FOR HEIGHT
FGFR3 inhibition is the most mechanistically coherent therapeutic target
for restoring BMP-driven growth in conditions where FGFR3 is overactive.
Vosoritide (CNP analogue) is already approved for achondroplasia.
These work by releasing the brake on BMP signalling, not by adding more BMP.
For children with growth plate pathology this is a real and active clinical area.
For healthy adolescents or adults seeking height increase, there is no
evidence-based BMP intervention currently available or in clinical trials.
BONE MORPHOGENETIC PROTEINS AND HEIGHT
BMP signaling | growth plate biology | chondrogenesis | what the science says
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
all citations are real peer-reviewed papers.
this is what the literature actually shows, presented directly.
[1] Nilsson O et al. (2007) Endocrinology. BMP-2 regulation of growth plate chondrogenesis and longitudinal bone growth
[2] Yoon BS, Lyons KM. (2004) J Cell Biochem. Multiple functions of BMPs in chondrogenesis
[3] Pogue R, Lyons K. (2006) Curr Top Dev Biol. BMP signaling in the cartilage growth plate
[4] Robert C et al. (2023) JBC. BMP-2 and Noggin interaction: molecular details of chondrogenesis inhibition
[5] Nilsson O et al. (2007) PLOS ONE. Spatial regulation of BMPs across growth plate zones
[6] Clinical and Experimental Pediatrics (2023). Growth plate closure and therapeutic interventions. PMC11551597
[7] Choi S et al. (2019) Mol Brain. Indirubin-3-oxime stimulates chondrocyte maturation via Wnt/BMP
[8] Yazaki Y et al. (1998) Spine. BMP-2/4 and OP-1 expression in rat epiphyseal growth plate
[9] Suttapreyasri S, Leepong N. (2013) J Craniofac Surg. BMP-2/7 and growth plate chondrocytes
[10] Kawai M et al. (2006) BMC MSK. BMP-2 and BMP-7 simultaneous gene transfer induces rapid bone formation
[11] Garrison KR et al. (2010) Health Technol Assess. rhBMP-2 review: evidence and complications
[12] Nature npj (2023). BMP2-hydrogel local therapy: growth plate fusion risk noted
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
CONTENTS
01 what BMPs are and how many exist
02 the growth plate how height actually happens
03 which BMPs are expressed in the growth plate and where
04 BMP-2 the primary chondrogenic driver mechanism in full
05 BMP-4 BMP-7 and the heterodimer effect
06 BMP antagonists Noggin Gremlin sclerostin why the brake exists
07 the Smad and non-Smad signaling cascades
08 the paradox too much BMP accelerates plate closure
09 growth plate closure why it happens and what drives it
10 therapeutic interventions that actually delay closure and increase height
11 what exogenous BMP could theoretically do and what the evidence shows
12 the honest translation open plates vs closed plates
13 verdict
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
01 WHAT BMPs ARE AND HOW MANY EXIST
Bone Morphogenetic Proteins (BMPs) are secreted signalling proteins
belonging to the TGF-beta superfamily. Despite their name, not all BMPs
promote bone formation. They are involved in embryonic patterning, organ
development, neural differentiation, and skeletal biology across species.
20 distinct BMPs have been identified in humans.
They signal through type I and type II serine-threonine kinase receptors.
Their activity is modulated by extracellular antagonists and co-receptors.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
THE BMP FAMILY RELEVANT TO HEIGHT
BMP-2
Most studied. Expressed throughout growth plate proliferative and hypertrophic zones. Primary driver of chondrocyte proliferation and hypertrophy. Confirmed to accelerate longitudinal bone growth concentration-dependently (Nilsson et al. 2007). The central figure of this thread.
BMP-4
Structural homolog of BMP-2. Co-expressed with BMP-2 in growth plate chondrocytes (Yazaki et al. 1998: marked expression in proliferating and maturing chondrocytes at 12 weeks in rat tibia). Forms heterodimers with BMP-7. Synergises with BMP-2 in osteochondral induction.
BMP-7 (OP-1)
Osteogenic Protein-1. Expressed in proliferating and maturing chondrocytes alongside BMP-2/4 (Yazaki 1998). Forms highly active heterodimers with BMP-2 and BMP-4. Kawai et al. 2006: simultaneous BMP-2 and BMP-7 gene transfer produced dramatically higher ALP activity and faster bone formation than either alone.
BMP-6
Expressed in hypertrophic chondrocytes of the growth plate. Role in regulating hypertrophic differentiation and eventual plate calcification. Less studied than BMP-2/4/7 in the height context.
GDF-5 (BMP-14)
Growth and Differentiation Factor 5. Expressed in joint interzone regions and growth plate. Loss-of-function mutations in humans cause brachydactyly type C (short fingers) and Grebe syndrome. Promotes chondrocyte differentiation. Dose-sensitive.
BMP-3
Paradoxical: BMP-3 is an INHIBITOR of bone formation and chondrogenesis. Acts as a negative regulator by competing at receptors. Elevated BMP-3 activity suppresses longitudinal growth. Not a therapeutic target for height increase.
BMP-9 (GDF-2)
Highly osteoinductive in vitro. Does not appear to play a primary role in growth plate chondrogenesis specifically. More relevant to osteoblast differentiation than chondrocyte function.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
02 THE GROWTH PLATE HOW HEIGHT ACTUALLY HAPPENS
Height is determined by longitudinal bone growth.
Longitudinal bone growth occurs at the epiphyseal growth plate.
The growth plate sits between the epiphysis and metaphysis of long bones.
When it closes, height stops. This is the fundamental constraint.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
THE THREE ZONES OF THE GROWTH PLATE
RESTING ZONE (reserve zone)
Small, sparsely distributed chondrocytes. Act as progenitor cells.
Slow replication rate. Supply progenitors to the proliferative zone.
BMP signalling maintains these cells in a quiescent state.
When progenitor cells here are depleted, growth plate senescence begins.
PROLIFERATIVE ZONE (columnar zone)
Flat chondrocytes arranged in columns along the long axis of the bone.
Replicate rapidly. This is where most of the actual height is generated.
BMP-2 is the primary driver of chondrocyte proliferation in this zone.
More cell divisions = more cells added to the column = more bone length.
HYPERTROPHIC ZONE
Chondrocytes undergo dramatic enlargement (hypertrophy).
Hypertrophic chondrocytes can increase their volume by 5-10x.
This enlargement directly contributes to longitudinal bone length.
Hypertrophic zone provides approximately 60% of total longitudinal growth.
BMP-2 stimulates hypertrophic differentiation in this zone.
Calcification occurs here. Vascular invasion. Bone replaces cartilage.
THE GROWTH PROCESS IN SEQUENCE
01 progenitors from resting zone enter proliferative zone
02 BMP-2 drives rapid chondrocyte division in columnar arrangement
03 daughter cells exit proliferative zone and hypertrophy
04 hypertrophic cells secrete collagen X and mineralisation signals
05 osteoblasts and blood vessels invade and replace hypertrophic cartilage with bone
06 new bone is added to the metaphysis. the bone is longer.
07 repeat continuously until plate senescence
Clinical and Experimental Pediatrics 2023 (PMC11551597):
the proliferative and hypertrophic zone activity, and the size of hypertrophic
chondrocytes, are the primary determinants of the rate of longitudinal growth.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
03 WHICH BMPs ARE EXPRESSED IN THE GROWTH PLATE AND WHERE
Yazaki et al. 1998 (Spine): immunohistochemical mapping of BMP-2/4,
OP-1 (BMP-7), and BMP receptors (BMPR-IA, BMPR-IB, BMPR-II) in rat
tibial growth plates at 12 and 24 weeks.
AT 12 WEEKS (actively growing plate):
BMP-2/4 and BMP-7: marked expression in proliferating and maturing chondrocytes
BMPR-IA, IB and II: clearly co-expressed in proliferating and maturing chondrocytes
BMPR expression decreased in hypertrophic chondrocytes
AT 24 WEEKS (plate beginning to senesce):
BMP-2/4 and BMP-7 expression decreased significantly
BMPR receptors still well-expressed in remaining proliferating chondrocytes
Temporal reduction of BMP ligand expression correlates with plate senescence.
Nilsson et al. (PLOS ONE 2017): BMP gradient analysis across growth plate zones.
BMP-related gene expression forms gradients from resting to hypertrophic zone.
Active BMP signalling confirmed in proliferative zone.
Smad7 (inhibitory Smad) quenches BMP signalling in the hypertrophic zone,
creating a natural dampening mechanism at the terminal differentiation stage.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
04 BMP-2 THE PRIMARY CHONDROGENIC DRIVER
Nilsson et al. 2007 (Endocrinology): the foundational growth plate BMP-2 study.
Fetal rat metatarsal bones cultured for 3 days with recombinant human BMP-2.
WHAT BMP-2 DID IN THIS EXPERIMENT
concentration-dependent acceleration of metatarsal longitudinal growth
stimulated chondrocyte proliferation in the epiphyseal zone (3H-thymidine assay)
increased chondrocyte hypertrophy (quantitative histology + enzyme histochemistry)
at highest dose: stimulated proteoglycan synthesis (glycosaminoglycan production)
THE NOGGIN CONFIRMATION THE MOST IMPORTANT FINDING
Noggin is an extracellular BMP antagonist. It binds BMP-2 and blocks its
receptor interaction. Adding Noggin reverses BMP-2's effects.
Key finding: when Noggin was added WITHOUT any exogenous BMP-2:
longitudinal bone growth decreased
chondrocyte proliferation decreased
chondrocyte hypertrophy decreased
This proves endogenous BMP-2 is actively driving growth in normal bone.
Block it: growth slows. Supplement it: growth accelerates.
BMP-2 is not a permissive signal. It is an active driver.
BMP-2 MOLECULAR MECHANISM AT THE GROWTH PLATE
BMP-2 binds BMPR-IA (ALK3) and BMPR-IB (ALK6) with BMPR-II as co-receptor.
Receptor complex phosphorylates R-Smads (Smad1, Smad5, Smad8).
R-Smad/Smad4 complex enters nucleus.
Activates Sox9 (master chondrocyte transcription factor).
Sox9 drives collagen II and aggrecan expression.
Drives Runx2 for hypertrophic differentiation.
Drives cell cycle progression via cyclin D1.
Net: more chondrocytes, bigger chondrocytes, more matrix. Longer bone.
NF-kB specifically activates BMP-2 gene expression in growth plate
chondrocytes both in vivo and in vitro (ScienceDirect, confirmed in vivo).
Inflammatory and mechanical signals feed back into BMP-2 transcription.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
05 BMP-4 BMP-7 AND THE HETERODIMER EFFECT
THE HETERODIMER DISCOVERY
BMPs naturally form both homodimers (BMP-2:BMP-2) and heterodimers
(BMP-2:BMP-7, BMP-4:BMP-7).
Heterodimers are significantly more potent than either homodimer alone.
Kawai et al. 2006 (BMC MSK): simultaneous gene transfer of BMP-2 and BMP-7
into rat calf muscles produced:
dramatically higher ALP activity vs either gene alone
better-defined bone opacities on soft X-ray at 10 days
advanced ossification on histological examination
BMP-4 mRNA also induced in response to the double transfer
The BMP-2 + BMP-7 combination does not simply add their effects.
It multiplies them. The heterodimer is a distinct, more potent ligand.
BMP-4 AT THE GROWTH PLATE
Co-expressed with BMP-2 in proliferating and maturing chondrocytes.
Shares BMPR-IA/BMPR-IB receptor preference with BMP-2.
Loss of Noggin (which blocks BMP-2/4/7) in mice: overgrowth of skeletal elements.
Misexpression of Noggin in chick limbs: reduction of skeletal elements.
Direct confirmation that BMP-4 activity is required for normal skeletal growth.
BMP-7 (OP-1) AT THE GROWTH PLATE
Yazaki 1998: OP-1 expressed markedly in proliferating and maturing chondrocytes
alongside BMP-2/4. The spatial co-expression pattern suggests cooperative action.
BMP-7 predominantly forms heterodimers with BMP-2 or BMP-4 in vivo.
Frontiers 2023: BMP-2 and BMP-7 synergise in osteochondrogenesis ex vivo.
Their combination stimulates both chondrogenic and osteogenic differentiation.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
06 BMP ANTAGONISTS NOGGIN GREMLIN SCLEROSTIN
BMP signalling in the growth plate is not unopposed. A system of extracellular
antagonists modulates BMP activity with spatial and temporal precision.
Understanding these antagonists is the key to understanding why the growth
plate eventually closes and what controls the rate of growth.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
NOGGIN
A cystine knot protein that binds BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, and GDF-5.
Robert et al. 2023 (JBC): crystal structure of BMP-2:Noggin complex resolved.
Noggin occupies the type I receptor binding epitope of BMP-2.
BMP-2 cannot bind BMPR-IA while Noggin is occupying the same site.
Noggin-BMP-2 Kd: approximately 0.02 nM. Extremely high affinity.
Noggin is the primary spatial regulator of BMP activity in the growth plate.
Functional consequence confirmed (Nilsson 2007):
Noggin added to cultured bone: growth slows, proliferation drops, hypertrophy drops.
Noggin removed from context: BMP-2 drives accelerated growth.
GREMLIN
DAN family antagonist. Binds BMP-2, BMP-4, BMP-7 with high affinity.
Expressed in the interdigital zone and joint-forming regions during development.
Frontiers 2023: Gremlin cannot induce fibrous differentiation on its own.
Works in concert with TGF-beta to control chondrocyte fate decisions.
SCLEROSTIN (SOST gene)
The connection to the Romosozumab thread. Sclerostin was identified as a
DAN family BMP antagonist with homology to Noggin (Winkler et al. 2003 EMBO J).
Primarily expressed by osteocytes. Inhibits BMP activity AND Wnt/LRP5-6.
Less well-characterised at the growth plate specifically than in mature bone.
Sclerosteosis patients (no sclerostin): skeletal overgrowth from childhood.
The BMP-inhibiting function of sclerostin is part of why these patients
have excess skeletal mass but also why Romosozumab's bone building works.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
07 THE SMAD AND NON-SMAD SIGNALING CASCADES
CANONICAL SMAD PATHWAY (primary growth plate mechanism)
BMP-2 binds BMPR-IA and BMPR-IB (type I) + BMPR-II (type II)
Type II receptor trans-phosphorylates type I receptor GS domain
Activated type I receptor phosphorylates R-Smads: Smad1, Smad5, Smad8
R-Smads complex with Co-Smad: Smad4
Complex translocates to nucleus
Activates BMP-responsive genes:
Sox9 master chondrocyte regulator, drives collagen II and aggrecan
Runx2 initiates hypertrophic differentiation
Id1/Id2 inhibitor of differentiation proteins, maintain progenitor state
ColII collagen type II, primary cartilage matrix protein
ColX collagen type X, marker of hypertrophic chondrocytes
VEGF drives vascular invasion of hypertrophic zone
Inhibitory Smads (Smad6, Smad7) compete with R-Smads to limit signalling.
Smad7 is specifically upregulated in the hypertrophic zone (Nilsson PLOS ONE).
This natural braking prevents excessive hypertrophic stimulation.
NON-SMAD PATHWAYS
BMP-2 also activates:
p38 MAPK stress kinase, additional chondrocyte differentiation driver
ERK1/2 proliferation and survival signalling
PI3K/Akt cell survival and growth factor signalling
TAK1 TGF-beta activated kinase 1, crosstalk with inflammatory signals
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
08 THE PARADOX TOO MUCH BMP ACCELERATES PLATE CLOSURE
This is the most important nuance in the whole thread.
More BMP is not always better for height. There is an optimal range.
WHAT HAPPENS WITH CONSTITUTIVELY ACTIVE BMP RECEPTOR
Nilsson et al. (PLOS ONE 2017): when constitutively active BMPR-IA was
expressed in cartilage, proliferative zone height was SHORTENED.
Chondrocyte proliferation was not affected.
But hypertrophic differentiation was ACCELERATED.
Interpretation: excessive BMP signalling pushes proliferative chondrocytes
into hypertrophy faster than they can be replaced by progenitors.
The proliferative zone shrinks. The plate thins. Growth rate decreases.
In extreme cases: premature growth plate closure.
Nature npj (2023): local BMP-2 hydrogel therapy in a porcine model of
Legg-Calve-Perthes disease showed increased areas of growth plate fusion.
The authors specifically warned: BMP-2 treatment may promote plate closure.
This is why the authors noted it may be most appropriate for patients
whose growth plates are not active.
THE DOSE-TIMING WINDOW
BMP-2 drives growth when it promotes PROLIFERATION faster than HYPERTROPHY.
BMP-2 closes the plate when it drives HYPERTROPHY faster than PROLIFERATION.
The balance between these two effects is dose-dependent and timing-dependent.
Nilsson 2007: lower doses stimulate growth. Higher doses may shift the balance.
There is no established therapeutic window for human height augmentation.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
09 GROWTH PLATE CLOSURE WHY IT HAPPENS
Clinical and Experimental Pediatrics 2023 (PMC11551597):
Growth plate senescence is the process that ends height.
THE SENESCENCE MECHANISM
progenitor cells in the resting zone are gradually depleted over time
proliferative chondrocyte numbers decrease
hypertrophic chondrocyte number and size decrease
the plate thins progressively
after senescence: hypertrophic chondrocytes replaced by osteocytes
extracellular matrix calcified and vascularised
growth plate fused: longitudinal bone growth complete
WHAT DRIVES CLOSURE THE PRIMARY SIGNALS
estrogen the primary closure signal. Both males and females.
testosterone is aromatised to estrogen which acts on the plate.
estrogen receptor alpha on chondrocytes accelerates hypertrophy.
this is why aromatase inhibitors delay closure and add height.
IGF-1 drives proliferative zone activity. works synergistically with BMPs.
GH stimulates local IGF-1 production in the growth plate.
thyroid hormone required for normal hypertrophic differentiation.
glucocorticoids at excess: severely impair growth (anti-proliferative).
TIMING OF CLOSURE IN HUMANS
distal radius and ulna: typically 16-18 years females / 18-20 years males
femur distal epiphysis: 17-19 years females / 18-20 years males
tibial proximal plate: 16-18 years females / 18-20 years males
vertebral growth plates: can remain partially active into early 20s
individual variation is significant. genetics are the primary determinant.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
10 THERAPEUTIC INTERVENTIONS THAT ACTUALLY DELAY CLOSURE AND INCREASE HEIGHT
These are real approved or investigational treatments with clinical evidence.
They are presented because they reveal the upstream pathway that BMPs feed into.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
GnRH ANALOGUES (leuprolide, triptorelin)
Suppress LH and FSH. Delay puberty. Delay estrogen-driven plate closure.
Used in precocious puberty to preserve height potential.
Effect: several additional centimetres of final height in clinical use.
Mechanism: reduce estrogen that drives closure. BMP signalling continues.
AROMATASE INHIBITORS (letrozole, anastrozole)
Block testosterone-to-estrogen conversion. Reduce closure signal.
Letrozole in adolescent males with growth failure: significant height gains.
Clinical and Experimental Pediatrics 2023: AI use delays growth plate closure
and increases predicted adult height. Off-label in most countries for this use.
C-TYPE NATRIURETIC PEPTIDE ANALOGUE (vosoritide)
FDA approved 2021 for children with achondroplasia (FGFR3 gain of function).
FGFR3 normally limits BMP signalling and chondrocyte proliferation.
CNP counteracts FGFR3 suppression, restoring BMP-driven growth plate activity.
In achondroplasia trials: increased annualised growth velocity significantly.
Mechanism directly involves restoring BMP-responsive growth plate activity.
FGFR3 INHIBITORS (infigratinib, palovarotene)
FGFR3 (fibroblast growth factor receptor 3) is a negative regulator of growth.
It suppresses BMP signalling and chondrocyte proliferation.
Inhibiting FGFR3 releases the brake on BMP activity at the plate.
Phase 3 trials ongoing in achondroplasia. Pre-clinical efficacy confirmed.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
11 WHAT EXOGENOUS BMP COULD THEORETICALLY DO
Taking the literature seriously: what would exogenous BMP administration
actually do if it reached the growth plate in sufficient concentration?
THE THEORETICAL POSITIVE CASE (open plates only)
Increased BMP-2 at the proliferative zone would:
accelerate chondrocyte division (confirmed, Nilsson 2007)
increase hypertrophic zone chondrocyte size (confirmed, Nilsson 2007)
upregulate Sox9 and ColII, maintaining chondrocyte phenotype
increase proteoglycan synthesis at high dose
theoretically: faster growth rate during the open plate window
THE PROBLEMS WITH EXOGENOUS BMP FOR HEIGHT
PROBLEM 1 DELIVERY TO THE GROWTH PLATE
The growth plate has a specific vascular supply. Systemic BMP administration
does not preferentially accumulate at growth plate chondrocytes.
BMP-2 half-life in vivo without carrier: approximately 7-16 minutes.
Local delivery to the growth plate is surgically invasive.
Topical or oral administration has no evidence of reaching the plate.
PROBLEM 2 THE CLOSURE PARADOX
As established in section 08: supraphysiological BMP at the plate
accelerates hypertrophic differentiation and can cause premature closure.
Nature npj 2023: local BMP-2 hydrogel increased growth plate fusion areas.
Attempting to use BMP to grow taller could close the plate faster.
PROBLEM 3 NO HUMAN TRIALS
No clinical trial has administered any BMP preparation to growing humans
for the purpose of height increase. All mechanistic data is animal or ex vivo.
The jump from rat metatarsal culture to human height augmentation
is not supported by any current clinical evidence.
PROBLEM 4 RHBMP-2 COMPLICATIONS AT SUPRAPHYSIOLOGICAL DOSES
See the rhBMP-2 thread for the full complication profile.
Ectopic bone, osteolysis, cancer signal, cardiovascular effects.
These are documented from orthopaedic surgical use, not height augmentation.
Applying that compound systemically to a growing adolescent is not studied.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
12 THE HONEST TRANSLATION OPEN PLATES VS CLOSED PLATES
IF YOUR GROWTH PLATES ARE STILL OPEN (typically under 18-20)
BMP signalling is already actively driving your height.
It is one of the primary endogenous systems doing exactly this.
The question of augmenting it exogenously runs into the delivery
problem and the paradoxical closure risk from supraphysiological dosing.
What IS evidence-based for maximising height in this window:
adequate sleep (GH pulse is largest during slow-wave sleep)
adequate nutrition: zinc, vitamin D, protein, calories
avoid glucocorticoid excess (suppresses BMP-driven chondrocyte proliferation)
avoid smoking (vasoconstrictive effects on growth plate vasculature)
treat any underlying endocrine issues (hypothyroidism impairs growth)
IF YOUR GROWTH PLATES ARE CLOSED (typically over 20-22)
No BMP intervention can reopen a fused growth plate.
Fused plates are bone. BMPs drive bone formation, not plate reopening.
The only interventions that affect height after closure:
spinal decompression / posture (millimetric, not centimetric)
limb lengthening surgery (Ilizarov / PRECICE nail: 5-8cm possible, major surgery)
No pharmacological intervention currently increases height after plate closure.
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
13 VERDICT
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
WHAT THE SCIENCE DEFINITIVELY SHOWS
BMPs, primarily BMP-2, are essential endogenous drivers of longitudinal bone growth.
They are expressed in the growth plate, they drive chondrocyte proliferation,
they stimulate hypertrophy, and blocking them with Noggin slows growth.
The biology is not in dispute. BMPs are part of how you grew tall.
THE ACTUAL OPPORTUNITY IN BMP BIOLOGY FOR HEIGHT
FGFR3 inhibition is the most mechanistically coherent therapeutic target
for restoring BMP-driven growth in conditions where FGFR3 is overactive.
Vosoritide (CNP analogue) is already approved for achondroplasia.
These work by releasing the brake on BMP signalling, not by adding more BMP.
For children with growth plate pathology this is a real and active clinical area.
For healthy adolescents or adults seeking height increase, there is no
evidence-based BMP intervention currently available or in clinical trials.
@northka @xorsizm @Nobodyreallycares @Luffy @Splankу @Hypertrophy @copevictim @Ghoultune @meh.guy @whore @yyoloo @klyro @doe.eyed_deer11 @ImNotSorry @rxpeangelz @sodium @iletheile @DEAN 2.0 @Noah Olivier Smith @widepalate @Ascending Machine @saint @sub3 chud @Recai @tomokoisliterallyme @gatetoheaven @darkerthangrey @tension @gaylien @animenerd123 @Neurodivergentt @thistimeiwontquit@10 @cutelittledaisyflower @OYASUMIAZI @ascendingthisyear @foidslayer @SevenColorCrystalBall @kora @Onyxae @1baar @emocel @derpy @JackthehammerJack @Rased @2400_nomie @Beani @benny @Angel @johnarcabob_reincarnated @Spongebob CirclePants @elvs @madma @melanotanjunky @chels_slayer @The Centipede @Dancin @Haurucky @BradyT @arniedagoats @Br4va @ankit13 @thanos5 @clark kent @Buff_miner77 @trueswan @submissivechud @Kalki.unbound.mindset @Byro @Forsaken Destiny @genio @iluvbunnys @Paradise @xoxo @Doe_eyes @lotuus @BigDihDiddy ⚦ @wutdamooo @Kitsune @PingPong @yielded @fallout @gimp @Eren Yeager's disciple @dontcallthemfoidsbro @JDD8 @vespertine @übermenschgrimreaper @ermhilol @leocopes @adelotes @Evilthinker21 @moonlight1 @windtl (@True king of LTNs @zennn @#sensitiveyoungwoman if you were not tagged but wish to be tagged in future post just reply to this)
) I don’t really wanna text more about this kind of stuff cause gatekeeping
